Survodutide Once Weekly for the Treatment of Adults with Obesity.

Summary

In a phase 3, double-blind RCT of 725 adults with obesity but without diabetes, once-weekly survodutide (3.6 or 6.0 mg) produced −12.2% and −13.0% mean weight loss at 76 weeks versus −5.4% with placebo. Gastrointestinal events were the most common adverse events and were usually mild-to-moderate.

Key Findings

• At week 76, mean body-weight change was −12.2% (3.6 mg) and −13.0% (6.0 mg) versus −5.4% with placebo.
• ≥5% weight loss was achieved in 72.6% and 71.9% with survodutide vs 46.3% with placebo (P<0.001).
• Gastrointestinal adverse events were common (81–90% on survodutide vs 48% placebo), typically mild-to-moderate; no deaths occurred.

Clinical Implications

Survodutide may offer a potent, once-weekly pharmacologic option for obesity management with clinically meaningful weight loss; clinicians should monitor for gastrointestinal tolerability.

Limitations

• Adverse events were predominantly gastrointestinal; long-term safety beyond 76 weeks remains to be characterized
• Exclusion of individuals with diabetes may limit generalizability to broader metabolic populations

Future Directions

Assess long-term safety and cardiometabolic outcomes, head-to-head comparisons with other advanced incretin-based or multi-agonist therapies, and real-world effectiveness.